Rosa Biotech accelerates NASH pre-clinical trial in liver disease
Bio-sensing pioneer secures £415,000 from angel investors Funding will accelerate non-alcoholic fatty liver disease (NAFLD / NASH)...
Rosa Biotech accelerates NASH pre-clinical trial in liver disease
Rosa publishes founding research in Nature Communications
Innovate Grant & New Starter
Introducing our new CEO: Dr Mark Street-Docherty
New arrivals at Rosa Biotech
Rosa Biotech win award at the Royal Society of Chemistry Emerging Technologies competition
Rosa Biotech raise £760,000 to develop groundbreaking biosensing platform